More Post from the Author
- Sasken Partners with VicOne to Deliver End-to-End Automotive Cybersecurity Solutions
- Helser Brothers to Showcase the One-of-a-Kind Motorized French Pole at CWC 2025
- ProCap BTC Announces Executive Team and Appreciation of its Bitcoin Holdings by More Than $60 Million in Less Than 90 Days
- One Park Financial Earns Great Place to Work Certification for the Eighth Time
- DRUID AI sammelt 31 Millionen Dollar in Serie C ein, um das Wachstum der Agentic-KI-Plattform unter dem neuen Geschftsfhrer Joseph Kim zu beschleunigen
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- Sasken Partners with VicOne to Deliver End-to-End Automotive Cybersecurity Solutions
- Helser Brothers to Showcase the One-of-a-Kind Motorized French Pole at CWC 2025
- ProCap BTC Announces Executive Team and Appreciation of its Bitcoin Holdings by More Than $60 Million in Less Than 90 Days
- One Park Financial Earns Great Place to Work Certification for the Eighth Time
- DRUID AI sammelt 31 Millionen Dollar in Serie C ein, um das Wachstum der Agentic-KI-Plattform unter dem neuen Geschftsfhrer Joseph Kim zu beschleunigen